

CORRECTION

Correction: Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010

The PLOS ONE Staff

There is an error in the CCBs column heading of [Table 3](#); the correct number is 5593. Please see the correct [Table 3](#) here.



OPEN ACCESS

Citation: The PLOS ONE Staff (2015) Correction: Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010. PLoS ONE 10(3): e0118763. doi:10.1371/journal.pone.0118763

Published: March 24, 2015

Copyright: © 2015 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Table 3. Multivariable adjusted risk ratios and 95% confidence intervals for initiating each antihypertensive medication class among Medicare beneficiaries in 2007–2010.

| Characteristic | Antihypertensive medication class initiated | | | | | | | |
|------------------------|---|--------------------|-------------------------------------|------------------------------|---|-----------------------------|--------------------|------------------------|
| | ACE-inhibitors (n = 10105) | ARBs (n = 4583) | Thiazide diuretics (n = 6040) | Loop diuretics (n = 3798) | Potassium- sparing diuretics (n = 973) | Beta blockers (n = 8658) | CCBs (n = 5593) | >1 class (n = 7961) |
| Year | | | | | | | | |
| 2007 | 1 (ref) | 1 (ref) | ref | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ref |
| 2008 | 0.95 (0.91–0.99) | 1.03 (0.95–1.11) | 0.99 (0.93–1.06) | 1.03 (0.95–1.11) | 1.07 (0.90–1.27) | 1.00 (0.95–1.05) | 1.00 (0.93–1.07) | 0.97 (0.92–1.02) |
| 2009 | 0.99 (0.95–1.04) | 0.99 (0.91–1.06) | 0.98 (0.92–1.04) | 1.03 (0.95–1.12) | 0.93 (0.78–1.11) | 1.00 (0.95–1.06) | 0.96 (0.90–1.03) | 0.97 (0.92–1.03) |
| 2010 | 0.98 (0.94–1.03) | 0.99 (0.92–1.07) | 0.92 (0.86–0.98) | 1.03 (0.95–1.12) | 0.90 (0.75–1.08) | 1.01 (0.96–1.06) | 0.98 (0.92–1.05) | 0.95 (0.90–1.00) |
| Age | | | | | | | | |
| 65–69 | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ref |
| 70–74 | 0.93 (0.89–0.97) | 0.95 (0.88–1.03) | 0.92 (0.87–0.98) | 1.09 (0.98–1.22) | 0.99 (0.82–1.18) | 1.02 (0.97–1.08) | 1.02 (0.94–1.10) | 0.90 (0.85–0.95) |
| 75–79 | 0.85 (0.81–0.90) | 0.96 (0.89–1.04) | 0.83 (0.77–0.89) | 1.41 (1.27–1.56) | 0.93 (0.77–1.13) | 1.01 (0.96–1.07) | 1.16 (1.07–1.25) | 0.89 (0.84–0.95) |
| 80–84 | 0.79 (0.75–0.84) | 0.85 (0.78–0.93) | 0.78 (0.73–0.84) | 1.69 (1.53–1.88) | 0.91 (0.74–1.12) | 1.09 (1.03–1.15) | 1.11 (1.02–1.20) | 0.86 (0.81–0.92) |
| 85+ | 0.73 (0.70–0.78) | 0.72 (0.65–0.79) | 0.67 (0.62–0.73) | 2.23 (2.02–2.46) | 0.88 (0.72–1.08) | 1.07 (1.01–1.14) | 1.20 (1.11–1.30) | 0.82 (0.77–0.87) |
| Male | 1.10 (1.06–1.13) | 0.84 (0.79–0.88) | 0.82 (0.78–0.86) | 1.00 (0.95–1.06) | 0.55 (0.47–0.64) | 1.01 (0.98–1.05) | 0.99 (0.94–1.04) | 0.95 (0.92–0.99) |
| Race/ethnicity | | | | | | | | |
| White | 1 (ref) | 1 (ref) | ref | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Black | 0.95 (0.89–1.00) | 1.00 (0.91–1.11) | 1.48 (1.38–1.58) | 0.80 (0.72–0.88) | 1.16 (0.94–1.43) | 1.00 (0.95–1.07) | 1.68 (1.57–1.80) | 1.48 (1.40–1.56) |
| Hispanic | 1.14 (1.05–1.24) | 1.28 (1.12–1.48) | 1.01 (0.88–1.16) | 0.66 (0.55–0.79) | 0.61 (0.37–1.02) | 0.96 (0.87–1.07) | 1.07 (0.93–1.23) | 1.03 (0.92–1.15) |
| Asian | 0.73 (0.65–0.82) | 1.80 (1.59–2.04) | 0.90 (0.77–1.06) | 0.48 (0.38–0.61) | 0.72 (0.44–1.16) | 1.04 (0.93–1.16) | 1.51 (1.33–1.71) | 1.00 (0.88–1.14) |
| Other | 1.03 (0.93–1.13) | 1.22 (1.04–1.43) | 0.94 (0.80–1.09) | 0.82 (0.67–1.01) | 1.19 (0.81–1.74) | 0.94 (0.83–1.06) | 1.44 (1.26–1.64) | 1.20 (1.07–1.35) |
| Medicaid buy-in | 1.01 (0.96–1.05) | 0.84 (0.78–0.90) | 0.79 (0.74–0.84) | 1.33 (1.25–1.42) | 0.67 (0.56–0.80) | 0.97 (0.93–1.02) | 0.95 (0.90–1.01) | 0.88 (0.83–0.92) |
| Diabetes | 1.35 (1.30–1.39) | 1.01 (0.95–1.08) | 0.82 (0.78–0.87) | 1.25 (1.18–1.33) | 0.58 (0.48–0.69) | 0.91 (0.88–0.95) | 0.83 (0.78–0.88) | 1.06 (1.01–1.10) |
| Coronary heart disease | 0.86 (0.82–0.90) | 0.75 (0.69–0.82) | 0.60 (0.55–0.65) | 1.12 (1.05–1.20) | 0.63 (0.51–0.79) | 1.74 (1.67–1.81) | 0.83 (0.77–0.89) | 0.96 (0.91–1.01) |
| Stroke | 1.12 (1.05–1.19) | 0.73 (0.64–0.83) | 0.60 (0.53–0.68) | 1.13 (1.03–1.24) | 0.71 (0.52–0.97) | 1.12 (1.05–1.19) | 1.25 (1.16–1.36) | 1.08 (1.01–1.16) |
| Chronic kidney disease | 0.79 (0.74–0.84) | 0.73 (0.65–0.81) | 0.62 (0.55–0.69) | 1.19 (1.10–1.28) | 0.64 (0.48–0.86) | 1.20 (1.14–1.27) | 1.47 (1.37–1.57) | 1.06 (1.00–1.13) |
| Heart failure | 0.90 (0.85–0.96) | 0.72 (0.65–0.81) | 0.54 (0.48–0.61) | 3.23 (3.03–3.45) | 0.52 (0.38–0.71) | 1.25 (1.19–1.32) | 0.85 (0.78–0.92) | 1.45 (1.37–1.53) |

Abbreviations: ACE = angiotensin-converting-enzyme; ARB = Angiotensin receptor blocker; CCB = Calcium channel blocker. The comparison group for each medication class initiated is not initiating that medication class. The comparison group for initiating more than one antihypertensive medication class is initiating only one medication class.

doi:10.1371/journal.pone.0118763.t001

Reference

1. Kent ST, Shimbo D, Huang L, Diaz KM, Kilgore ML, Oparil S, et al. (2014) Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010. PLoS ONE 9(8): e105888. doi:[10.1371/journal.pone.0105888](https://doi.org/10.1371/journal.pone.0105888) PMID: [25153199](https://pubmed.ncbi.nlm.nih.gov/25153199/)